Safety Study of JTT-302 in Subjects With Low HDL-C Levels

An Eight Week, Open-label Extension Study Evaluating the Safety of JTT-302 Administered Once Daily in Subjects With Low HDL-C Levels Who Have Completed the Treatment Phase of Study AT302-U-06-003

The purpose of this study is to evaluate the safety of JTT-302 when administered for eight or 12 weeks in subjects with low HDL-C levels and to determine the effect of JTT-302 on lipid parameters and CETP activity and mass.

Inclusion Criteria:

• Subjects must have successfully completed the 4-week treatment period of study AT302-U-06-003

Exclusion Criteria:

• Females who are pregnant or lactating, and females of child bearing potential who are not using an effective method of contraception
• Use of Cytochrome P450 3A4 inducers or inhibitors, as defined in the protocol
• Subjects who cannot follow the prescription and OTC medication restrictions defined in the protocol
• Flu-shots not permitted during the study, including the follow-up period.